Lestaurtinib, a tyrosine kinase inhibitor, enhanced the in-vitro drug effects of the PARP1 inhibitor AG14361 in breast cancer treatment, partly by suppressing NF-κB signaling [68]. Here, NFKB1 is linked to breast carcinoma.